IVIG may reduce seizure frequency in some children with drug-resistant epilepsy, especially those with generalized seizures.

Ocrevus is now FDA approved to treat relapsing-remitting multiple sclerosis in children aged 10 years and older weighing at least 25kg.

A new research published in the Journal of the American Medical Association revealed that out of children presenting to the ...

The US FDA has approved ocrelizumab (Ocrevus, Genentech) intravenous infusion for children aged 10 years and older with relapsing-remitting multiple sclerosis (RRMS) who weigh at least 55 lbs (25 kg), ...

ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, ...

Clinical data from a 16-patient pediatric study demonstrate the safety and efficacy of Asceniv in younger populations, ...

Ultomiris offers major market opportunities through its long-acting C5 inhibition, leading to significant patient convenience and compliance with fewer infusions. Rapid conversion from older therapies ...

Broward Children's Center (BCC) – a nonprofit organization dedicated to serving infants, children and young adults who are ...

Bhagwant Mann Govt’s Mukh Mantri Sehat Yojana Shields Punjabi Families from Summer Health Crisis, 3,279 Patients Receive ...

Axial involvement and osteoporosis were significantly associated with treatment switching among patients with pediatric CNO.

Organon to present 8 abstracts on affordability, access and adoption across women’s health, biosimilar and general medicines portfolio at ISPOR 2026.

SAN DIEGO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- via IBN -- Sapu Nano and Oncotelic (OTCQB: OTLC) today announced that the first patient has been dosed in the Phase 1b clinical trial of Sapu003, ...